Loading...
•
Dec 31, 2022
ACADIA Q4 2022 Earnings Report
Acadia Pharmaceuticals reported Q4 2022 financial results with NUPLAZID net sales increasing by 4% compared to Q4 2021.
Key Takeaways
Acadia Pharmaceuticals reported Q4 2022 results, featuring NUPLAZID net sales of $136.5 million, a 4% increase from Q4 2021. The company's net loss for the quarter was $41.7 million, or $0.26 per share. The company is preparing for a transformative year in 2023 with potential FDA approval of trofinetide and advancement of its pipeline programs.
NUPLAZID net sales were $136.5 million for Q4 2022, a 4% increase compared to $130.8 million in Q4 2021.
Full year 2022 NUPLAZID net sales reached $517.2 million, a 7% increase over 2021.
The company's New Drug Application for trofinetide for the treatment of Rett syndrome has a PDUFA action date of March 12, 2023.
Acadia expects net NUPLAZID sales in the range of $520 to $550 million for the full year 2023.
ACADIA
ACADIA
ACADIA Revenue by Segment
Revenue by Segment
NUPLAZID Sales Revenue
CapyFin.com Forward Guidance
Acadia Pharmaceuticals provided financial guidance for the full year 2023.
Positive Outlook
- Net NUPLAZID sales are expected to be in the range of $520 to $550 million.
- R&D expense is projected to be in the range of $235 to $255 million on a GAAP basis, including approximately $20 million of stock-based compensation expense.
- SG&A expense is expected to be in the range of $360 to $380 million on a GAAP basis, including approximately $45 million of stock-based compensation expense.